US009561197B2

(12) **United States Patent**
Scharschmidt et al.

(10) **Patent No.: US 9,561,197 B2**
(45) **Date of Patent: *Feb. 7, 2017**

(54) **METHODS OF THERAPEUTIC MONITORING OF PHENYLACETIC ACID PRODRUGS**

(75) Inventors: **Bruce Scharschmidt**, San Francisco, CA (US); **Masoud Mokhtarani**, Walnut Creek, CA (US)

(73) Assignee: **Horizon Therapeutics, LLC**, Lake Forest, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 649 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **13/610,580**

(22) Filed: **Sep. 11, 2012**

(65) **Prior Publication Data**

US 2013/0281530 A1 Oct. 24, 2013

Related U.S. Application Data

(60) Provisional application No. 61/636,256, filed on Apr. 20, 2012.

(51) **Int. Cl.**

A61K 31/192	(2006.01)
A61K 31/216	(2006.01)
A61K 31/225	(2006.01)
G01N 33/68	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/192*** (2013.01); ***A61K 31/216*** (2013.01); ***G01N 33/6812*** (2013.01)

(58) **Field of Classification Search**

CPC A61K 31/192; A61K 31/216

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,284,647	A	8/1981	Brusilow
4,457,942	A	7/1984	Brusilow
5,654,333	A	8/1997	Samid
5,968,979	A	10/1999	Brusilow
6,060,510	A	5/2000	Brusilow
6,083,984	A	7/2000	Brusilow
6,219,567	B1	4/2001	Eggers
8,094,521	B2	1/2012	Levy
8,404,215	B1	3/2013	Scharschmidt et al.
8,642,012	B2	2/2014	Scharschmidt
2003/0195255	A1	10/2003	Summar
2004/0229948	A1	11/2004	Summar
2005/0273359	A1	12/2005	Young
2006/0135612	A1	6/2006	Ferrante
2008/0119554	A1	5/2008	Jalan
2010/0008859	A1	1/2010	Scharschmidt
2010/0016207	A1	1/2010	Wurtman et al.
2012/0022157	A1	1/2012	Scharschmidt
2012/0220661	A1	8/2012	Lee
2013/0210914	A1	8/2013	Scharschmidt
2014/0142186	A1	5/2014	Scharschmidt et al.

FOREIGN PATENT DOCUMENTS

WO	WO94/22494	10/1994
WO	WO 2005/053607	6/2005
WO	WO 2006/056794	6/2006
WO	WO 2007/005633	1/2007
WO	WO 2009/087474	7/2009
WO	WO 2009/134460	11/2009
WO	WO 2010/025303	3/2010
WO	WO 2012/028620	3/2012
WO	WO2013/048558	4/2013
WO	WO2013/158145	10/2013

OTHER PUBLICATIONS

Ambrose, A.M., (1933) "Further Studies on the Detoxification of Phyenylacetic Acid." *J Biol Chem* 101:669-675.

Batshaw M.L. et al. (Dec. 1980) "Treatment of Hyperammonemic Coma Caused by Inborn Errors of Urea Synthesis," *J Pediatr* 97(6):893-900.

Batshaw M.L. et al. (Jun. 10, 1982) "Treatment of Inborn Errors of Urea Synthesis: Activation of Alternative Pathways of Waste Nitrogen Synthesis and Excretion," *N. Engl J Med* 306(23):1387-1392.

Batshaw, M.L. (1984) "Hyperammonemia," in Current Problems in Pediatrics, Lockhart, J.D. ed.: Year Book Medical Publishers, pp. 2-69.

Batshaw, M.L. et al. (Aug. 1981) "New Approaches to the Diagnosis and Treatment of Inborn Errors of Urea Synthesis," *Pediatrics* 68(2):290-297.

Berry, G.T. et al., (2001) "Long-term Management of Patients with Urea Cycle Disorders." *J Pediatrics* 138:S56-S61.

Brahe, C., et al., (2005) "Phenylbutyrate Increases SMN Gene Expression in Spinal Muscular Atrophy Patients," *Eur J Hum Genet* 13:256-259.

Brunetti-Pierri, N., et al., (2011) "Phenylbutyrate Therapy for Maple Syrup Urine Disease," *Hum Mol Genet* 20(4):631-640.

Brusilow, S.W., et al. (Sep. 1, 1979) "New Pathways of Nitrogen Excretion in Inborn Errors of Urea Synthesis," *Lancet* 2(8140):452-454.

Brusilow, S.W., et al. (Feb. 8, 1980) "Amino Acid Acylation: A Mechanism of Nitrogen Excretion in Inborn Errors of Urea Synthesis," *Science* 207:659-661.

Brusilow, S.W., et al. (Jun. 21, 1984) "Treatment of Episodic Hyperammonemia in Children With Inborn Errors of Urea Synthesis," *N. Engl J Med* 310(25):1630-1634.

Brusilow, S.W., et al. (1991) Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion. *Pediatric Res* 29(2):147-150.

Brusilow, S.W., et al. (1991) "Treatment of Urea Cycle Disorders," Chapter 5 in Treatment of Genetic Diseases, Desnik, R.J. et al. eds, Churchill Livingstone, New York, New York, pp. 79-94.

Brusilow, S.W., et al. (1993) "Restoration of Nitrogen Homeostasis in a Man with Ornithine Transcarbamylase Deficiency." *J Metabolism* 42:1336-1339.

Brusilow, S.W., et al. (Jul. 25, 1994—Amendment Dated) "Protocols for Management of Intercurrent Hyperammonemia in Patients with Urea Cycle Disorders," FDA Application to Market a New Drug for Human Use or an Antibiotic Drug for Human Use, 14 pages.

Brusilow, S.W., et al. (1995) "Urea Cycle Disorders: Clinical Paradigm of Hyperammonemic Encephalopathy." *Prog Liver Diseases* 12:293-309.

Brusilow, S.W., et al. (1995) "Urea Cycle Enzymes," Chapter 32 in The Metabolic and Molecular bases of Inherited Diseases, Scriver, C.R. et al. eds., McGraw-Hill, Inc. New York, New York, pp. 1187-1232.

(Continued)

Primary Examiner — Jeffrey S Lundgren
Assistant Examiner — Sara E Townsley

(57) **ABSTRACT**

The present disclosure provides methods for adjusting the dosage of PAA prodrugs (e.g., HPN-100, PBA) based on measurement of PAA and PAGN in plasma and calculating the PAA:PAGN ratio so as to determine whether PAA to PAGN conversion is saturated.

2 Claims, 7 Drawing Sheets